Clinical Trial Update: Safety and Efficacy of Trastuzumab BS

View source ↗

Summary

Pfizer's trastuzumab biosimilar (Trastuzumab BS) in gastric cancer has completed the trial. Results were posted on 2026-04-14, assessing safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Trastuzumab BS (trastuzumab)

Snippet

Sponsor: Pfizer | Conditions: Gastric Cancer | Status: COMPLETED | Results posted: 2026-04-14